Hematologic Malignancy
Childhood B Acute Lymphoblastic Leukemia
CI-CAN-00002201Explore in graph →
PediatricHematologic7 active trials
- NCIt
- C9140
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002201Explore in graph →
Clinical trials
36 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07422337 | A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab(BOOSTER) | recruiting | — | 300 | Arkansas Children's Hospital Research Institute |
| 1 |
| Feb 25, 2026 |
| clinicaltrials |
| NCT06287528 | A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04722848 | Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | active not recruiting | Phase 3 | 236 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04475731 | Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse | active not recruiting | Phase 2 | 67 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06175702 | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL(LALPh2022) | not yet recruiting | — | 150 | PETHEMA FoundationOTHER | 0 | Dec 19, 2023 | clinicaltrials |
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | not yet recruiting | Phase 2 | 22 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT04746209 | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | recruiting | Phase 2 | 25 | Medical College of WisconsinOTHER | 1 | Sep 17, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials